The Cordish family. Source: Cordish Companies.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The CD Private Equity Fund Series, which consists of three ASX-listed funds and one private fund, has released its latest half-year updates
  • Fund III (CD3) reported the best increase in investment income, jumping up 892 per cent to $44.2 million, with an operating profit of $40.6 million
  • Fund II (CD2) recorded a 340.3 per cent jump in investment income to $25.6 million, while Fund I (CD1) hit $11.9 million in investment income, up 246.6 per cent
  • All of the funds offer investments in small-to-mid sized private investment funds and companies which are based in North America
  • Shares in CD1 opened Tuesday at $1.38, while CD2 was trading at $1.66 and CD3 for $1.85

The CD Private Equity Fund Series has released its latest half-year update for all three of its ASX-listed funds.

The series consists of the three listed funds as well as a fourth unlisted fund with each offering investments in small-to-mid sized US private investment funds and companies.

Fund III (CD3) reported the best increase in investment income over the six month period, jumping up 892 per cent to $44.2 million, with an operating profit of $40.6 million.

This fund is the newest of CD’s listed funds and gave investors total returns of 27.5 per cent on a post-tax net asset value basis over the six months to September 30.

Fund II (CD2) recorded a 340.3 per cent jump in investment income to $25.6 million and a net operating profit of $21.4 million and total returns of 21.3 per cent.

Finally, Fund I (CD1) hit $11.9 million in investment income, up 246.6 per cent, and recorded an operating profit of $10.8 million.

CD1 has eight underlying fund managers and is the older of the CD Private Equity funds, offering returns of 23.1 per cent on a post-tax net asset value basis.

All of CD Private Equity’s listed funds are backed by the Cordish families, who own the US-based real estate and entertainment business, Cordish Companies.

Shares in CD1 opened Tuesday at $1.38, while CD2 was trading at $1.66 and CD3 for $1.85 at the open of market on November 30.

CD1 by the numbers
More From The Market Herald

" Live Verdure (ASX:LV1) partners with TruLife for US distribution

Food, skincare and nutraceutical company Live Verdure (ASX:LV1) has entered a non-executive national sales and distribution…
SECOS Group (ASX:SES) - CEO, Ian Stacey

" SECOS (ASX:SES) launches MyEcoBag and MyEcoPet through Pacchini

Sustainable packaging company, SECOS (ASX:SES) has launched MyEcoBag and MyEcoPet through Pacchini Sales and Distribution to…

" Solis Minerals (ASX:SLM) kicks off drilling at Mostazal copper project

Newly listed Solis Minerals (ASX:SLM) has hit the ground at its Mostazal copper project in Chile…
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies